Leading Infectious Disease Biomaterial Manufacturer

  • Copan FLOQSwab® and Liquid Control Products
    • Clinical Diagnostics,
    • Proficiency Programs,
    • Training, Verification and Development
  • Antigens for Diagnostic Test Manufacturers
  • Viral Transport Medium – DxTM™

Microbix Reports Results for Q3 Fiscal 2022

Q3 Sales of $5.0 million, Q3 Net Earnings of $0.6 million MISSISSAUGA, August 11, 2022 - Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF,...

Microbix Executes Substantial QAPs Supply Agreement

Microbix QAPs to Support Molecular & Antigen Test Platforms for Multiple Diseases MISSISSAUGA, CANADA, August 10, 2022 – Microbix Biosystems...

Microbix Presenting STI Multiplex Test Controls at AACC

Quality Control Materials for Genital Ulcer Disease Molecular Assays MISSISSAUGA, CANADA, July 26, 2022 – Microbix Biosystems Inc. (TSX: MBX, OTCQX:...


Why choose Microbix Quality Assessment Products (QAPs)? Find out more.


Microbix produces one of the world’s broadest range of infectious disease antigens.


Microbix has a partnership opportunity. Check it out here.

Our Commitment to Quality

Our quality process ensures our customers receive products that meet and exceed their needs and expectations. Our quality management system takes into consideration regulatory requirements that are applicable to the type of products we manufacture and the industries we serve.